Biogen Inc. (BIIB) and Apellis Pharmaceuticals (APLS) announced they have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE.
The acquisition is expected to be increasingly accretive to Biogen's Non-GAAP EPS starting in 2027. The transaction is expected to meaningfully increase Biogen's non-GAAP EPS compounded annual growth rate through the end of the decade.
In pre-market trading on NasdaqGS, Apellis shares are up 140.5 percent to $41.10.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.